Substituted beta-phenyl-alpha-hydroxy propanoic acid, synthesis method and use thereof
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cardiovascular and cerebrovascular diseases using salvianic acid derivatives are limited by their inability to effectively cross the cardiocerebral barrier, necessitating the development of modified β-phenyl-α-hydroxylpropionic acid derivatives with enhanced potency and therapeutic effects.
Innovation Solution
A process for synthesizing substituted β-phenyl-α-hydroxy-propionic acid derivatives, specifically compounds with varied functional groups, is developed to enhance their ability to cross biological barriers and improve therapeutic efficacy for cardiovascular and cerebrovascular diseases, involving reactions with specific catalysts and solvents to produce compounds like bornyl β-(3,4-dihydroxylphenyl)-α-hydroxylpropionate ester.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If salvianic acid derivatives are used for treatment of cardiovascular and cerebrovascular diseases, then therapeutic effects are achieved, but the ability to cross cardiocerebral barrier is insufficient
Solution Approach 1:
The patent modifies the chemical structure of salvianic acid derivatives by substituting hydroxyl groups with various functional groups (methoxy, ethoxy, halogens, acyloxy) to change the molecular properties. This structural modification enables the derivatives to cross the cardiocerebral barrier while maintaining or enhancing their therapeutic effects on cardiovascular and cerebrovascular diseases
Solution Approach 2:
The patent creates composite molecular structures by combining the core β-phenyl-α-hydroxylpropionic acid scaffold with various substituent groups (R1-R5). These composite structures integrate the pharmacological activity of the parent compound with the barrier-crossing capability of the substituted groups, particularly borneol moieties
2Object-affected harmful factors
If β-phenyl-α-hydroxylpropionic acid is modified by incorporating borneol structure, then ability to pass through cardiocerebral barrier is improved, but synthesis complexity increases
Solution Approach 1:
The synthesis process is divided into distinct stages: first forming the core β-phenyl-α-hydroxylpropionic acid structure, then sequentially introducing substituent groups including borneol moieties. This segmented approach allows each modification step to be optimized independently, managing overall synthesis complexity while achieving the desired barrier-crossing capability
Solution Approach 2:
The patent employs various catalysts (concentrated H2SO4, silicotungstic acid, phosphomolybdic acid, p-toluene sulfonic acid, aluminum trichloride, zinc chloride, magnesium chloride) as intermediaries to facilitate the complex substitution reactions. These catalysts enable the incorporation of borneol structures and other functional groups without requiring overly complex synthetic pathways
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The synthesized derivatives demonstrate improved potency and therapeutic effects, including increased cerebral microcirculatory blood flow and reduced myocardial infarction areas, suggesting potential for enhanced treatment and prevention of cardiovascular and cerebrovascular diseases.
Implementation Method 1
reacting a compound of the formula (III) with a compound of formula (IV) or a hydrate thereof in the presence of a catalyst
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention relates to a compound of the formula (I), wherein R1, R2 and R3 are each independently selected from H, OH, F, Cl, Br, methoxy and ethoxy; or alternatively, R1 and R2 together form -OCH2O-, R3 is selected from H, OH, methoxy, ethoxy and halogens; R4 is OH or acyloxy; R5 is cycloalkoxyl, amino and substituted amino, and when R5 is selected from amino, at least one of R1, R2 and R3 is not H. The present invention further relates to a process for synthesizing a compound of the formula (I), and use of the compound of the formula (I) in the manufacture of a medicament for the prevention or treatment of cardiovascular or cerebrovascular diseases.